Preexisting allergic disease may increase risk for long COVID
Nov 15, 2023
A systematic literature review identifies an increased risk but with very low certainty.
Tezepelumab reduces mucus plugs in adults with uncontrolled asthma
Sep 29, 2023
The reduction in mucus plug scores correlates with improvements in lung function and reductions in inflammatory markers.
Wildfire PM2.5 linked to increase in incidence of asthma ED visits
Aug 28, 2023
In stratified analyses, the wildfire PM2.5 asthma effect was more pronounced in those aged 18 to 65 years versus those aged younger than 18 years or older than 65 years.
Review shows certain exercises benefit patients with asthma
Aug 14, 2023
Yoga, breathing control practices and aerobic training show benefits.
Frequent green space visits linked to lower use of certain meds
Jan 19, 2023
Lower use of psychotropic, antihypertensive and asthma medications were observed; the association was attenuated by body mass index.
FDA approves new two-drug combo medicine for asthma
Jan 12, 2023
The medication is the first approved in the United States to contain an inhaled corticosteroid as a reliever rather than as a controller of asthma symptoms.
The necessity of clean tech and indoor air quality in assisted living
By
Tony Abate
Jan 12, 2023
Owners and operators who take advantage of indoor air quality technology can support lower vacancy rates, improve health and safety for residents and drive public and stakeholder confidence.
Asthma exacerbations up after relaxation of COVID-19 restrictions
Nov 28, 2022
The relaxation of restrictions coincided with an increasing incidence of COVID-19, non-COVID-19 ARI and severe asthma exacerbations.
Traffic-related air pollution may impact women more
Sep 20, 2022
The effects on plasma proteins known to play a role in inflammation, oxidative stress and cardiovascular disease are greater in women than in men.
Asthma drug fluticasone fails as potential COVID-19 treatment
Jul 14, 2022
The finding is from a nationwide study of 5,000 participants that continues to evaluate existing drugs to treat mild-to-moderate COVID-19.
